POSTER LISTING:

PROFFERED PRESENTATIONS

POSTER SESSION A

POSTER SESSION B

*Current as of November 22, 2023*
Proffered Presentations

*current as of November 22, 2023


PR002, A008  Somatic mutation rates and strength of selection on driver genes change by age in melanoma. Yihan Liu, Yale School of Public Health, New Haven, Connecticut.


PR005, A015  Tracing the clonal dynamic of metastatic castration-resistant prostate cancer over immunotherapy using circulating tumor DNA. Chennan Li, National Cancer Institute, Bethesda, Maryland.

PR006  Evolution of evolvability. Jill A. Gallagher, Moffitt Cancer Center, Tampa, Florida.

PR007, A034  Molecular subtyping of lung adenocarcinoma premalignant lesions identifies features associated with aggressive disease. Kelley Anderson, Boston University, Boston, Massachusetts.

PR008, A041  Cell state transitions drive the evolution of disease progression in B-cell acute lymphoblastic leukemia. Jeffrey West, Moffitt Cancer Center, Tampa, Florida.


PR010, B006  Linking proliferation rate to the evolution of single-cell primary and metastatic tumor clones. Olivia Lucas, University College London, London, United Kingdom.

PR011  Comprehensive longitudinal tracking of lung cancer evolutionary clonal dynamics during therapy using circulating tumour DNA. Alexander M. Frankell, Early Cancer institute, University of Cambridge, Cambridge, United Kingdom.

PR012  Evolutionary dynamics of whole-genome doubling in ovarian cancer. Ignacio Vázquez-García, Memorial Sloan Kettering Cancer Center, New York, New York.


PR014  Multiregion biopsies and corresponding neurosphere cultures reveal spatial divergence in glioblastoma evolution. Michalina Janiszewska, The Wertheim UF Scripps Institute, Jupiter, Florida.

PR016, B017  Topology of the tumor microenvironment: Integrating imaging, modeling, and topological data analysis. Rowan Barker-Clarke, Cleveland Clinic, Cleveland, Ohio.

PR017, B030  Properties of somatic methylation changes in human hematopoietic stem cells in health and disease. Lori D. Kregar, Wellcome Sanger Institute, University of Cambridge, Cambridge, United Kingdom.

PR018, B035  Adaptive local fitness landscapes for aneuploid karyotypes. Noemi Andor, Moffitt Cancer Center, Tampa, Florida.
Poster Session A

Monday, December 4

5:45-7:15 p.m.

*current as of November 22, 2023

A001  Genomic signatures of past and present chromosomal instability in Barrett’s esophagus and early esophageal adenocarcinoma. Chunyang Bao, Dana-Farber Cancer Institute, Boston, Massachusetts.

A002  Cardiovascular diseases predominate inflamminging causes of death among patients with prostate cancer: A population-based analysis using the SEER database. Amr Ebied, University of South Florida, Tampa, Florida.

A004  Comparison of ctDNA detection in seven different types of body liquids from patients with metastatic breast cancer. François Richard, KU Leuven, Leuven, Belgium.

A005  Quantification of cancer effect sizes of somatic variants reveals stage-dependent evolution in primary and metastatic skin cutaneous melanoma. Rishi M. Shah, Yale College, New Haven, Connecticut.

A006  Cancer origin tracing and timing in two high risk prostate cancers using multisample whole genome analysis: Potential clinical value. Serafiina Jaatinen, Tampere University, Tampere, Finland.

A007  Picturing progression: A new role of whole slide imaging in comprehensive clinical genomic datasets. Elizabeth G. Sweeney, ConcertAI, Plymouth Meeting, Pennsylvania.

A009  The logic of evolution traps in triple negative breast cancer. Zachary T. Compton, Moffitt Cancer Center, Tampa, Florida.

A010  Longitudinal histology and spatial transcriptomics profiling in targeted treatment of melanoma patient-derived models interrogates persister and resistant cell populations. Sergii Domanskyi, The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.


A012  Emergence of MEK1 mutations in RAF or RAS-mutant solid tumors following treatment with a combination of selective type II RAF inhibitor belvarafenib and MEK inhibitor cobimetinib. Stephanie Hilz, Genentech, Inc., South San Francisco, California.
A013  Cell-extrinsic mechanisms of accelerated therapy resistance mediated by altered pharmacokinetics. Pragya Kumar, University of South Florida and Moffitt Cancer Center, Tampa, Florida.


A016  Positive ecological interaction between therapy-resistant and sensitive cells, mediated by stromal niche, slows the expansion of resistant subpopulations and promotes tumor heterogeneity. Andriy Marusyk, Moffitt Cancer Center, Tampa, Florida.

A017  Computational and mouse models of adaptive therapy with multiple drugs in breast cancer. Carlo C. Maley, Arizona State University, Tempe, Arizona.


A019  The role of tumor transcriptional variability in evading acute CD8+ T cell exposure in melanoma. Raymond W. S. Ng, University of Pennsylvania, Philadelphia, Pennsylvania.

A020  An early determination of patients’ eligibility for a bladder cancer immunotherapy using a data science approach. Kayode D. Olumoyin, Moffitt Cancer Center, Tampa, Florida.

A021  Evolutionary immunotherapy in NSCLC: An integrated approach. Sandhya Prabhakaran, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

A022  Dissecting patterns of small cell lung cancer evolution using deep whole genome sequencing of circulating tumor DNA. Benjamin B. Morris, University of Texas MD Anderson Cancer Center, Houston, Texas.

A023  Integrating mathematical modeling and in vitro experiments to measure ecological interactions in cancer. Maximilian A. R. Strobl, Cleveland Clinic, Cleveland, Ohio.

A024  Ploidy as a predictive biomarker for gemcitabine sensitivity in triple-negative breast cancers. Vural Tagal, Moffitt Cancer Center, Tampa, Florida.


A027  Detecting and modeling frequency-dependent evolution in serially passaged primary triple negative breast cancer patient derived xenografts. Thomas A. Veith, Moffitt Cancer Center, Tampa, Florida.

A030  Dynamical modeling of proliferative-invasive plasticity and IFNγ signaling in melanoma reveals mechanisms of PD-L1 expression heterogeneity. Mohit Kumar Jolly, Indian Institute of Science, Bangalore, India.

A031  Investigating the mechanism and impact of frequency-dependent interactions in non-small cell lung cancer. Eshan S. King, Case Western Reserve University School of Medicine, Cleveland, Ohio.
A032  **Cellos: High-throughput deconvolution of 3D organoid dynamics at cellular resolution for cancer pharmacology.** Patience Mukashyaka, The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.

A033  **Programmed evolution: Using asexual gene drives to sculpt tumor populations and combat genetic diversity.** Justin Pritchard, Pennsylvania State University, University Park, Pennsylvania.

A035  **Mutation of NOTCH1 is selected within normal esophageal tissues, yet leads to selective epistasis suppressive of further evolution into cancer.** Kira A. Glasmacher, Emmanuel College, Boston, Massachusetts.

A036  **The genetic landscape of head and neck cancer using brush biopsy.** Evit John, University of Texas MD Anderson Cancer Center, Houston, Texas.

A037  **Investigating the role of the somatic DDX41 variant in the context of DDX41 hereditary myeloid malignancy syndromes (HMMS).** Ludovica Marando, Mayo Clinic, Rochester, Minnesota.

A039  **Metabolic evolution in breast cancer predicts organ-specific metastasis.** Deepti Mathur, Memorial Sloan Kettering Cancer Center, New York, New York.

A040  **Suppressing the cytomatrix elastic solid phase of cytoplasm will eliminate the root cause of cancer.** Tattym E. Shaiken, Baylor College of Medicine, Houston, Texas.

A042  **Prognostic worth of Nrf2/BACH1/HO-1 signals in the development of breast cancer.** Precious Barnes, University of Cape Coast, Cape Coast, Ghana.
Poster Session B
Tuesday, December 5
5:45-7:15 p.m.
*current as of November 22, 2023

B001 Elucidating metastatic pathways in pediatric cancers. Natalie Andersson, Division of Clinical Genetics, Faculty of Medicine, Lund University, Lund, Sweden.

B002 Profiling intra-tumor heterogeneity and chromosomal instability in malignant peripheral nerve sheath tumors. Yixiao Cheng, University of Texas MD Anderson Cancer Center, Houston, Texas.


B008 The polyclonal path towards malignant transformation in familial adenomatous polyposis. Ryan O. Schenck, Stanford University, Palo Alto, California.

B010 BRCA gene variants and mutational signatures exhibit not only prevalence and statistical significance, but also substantial cancer effect in tumors of Hispanic populations. Bohan Zheng, The Peddie School, Yale School of Public Health, Hightstown, New Jersey.

B011 Lower incidence of small intestinal adenocarcinomas may be due to constrained copy number karyotype and increased immune surveillance. Salpie Nowinski, Institute of Cancer Research, London, United Kingdom.

B012 Developing applications for a new, fully automated, low-coherence, label free, time lapse holotomographic analysis platform-TomoCube HT-X1: Preparations for AI based analysis. Ed A. Luther, Northeastern University, Boston, Massachusetts.

B013 Development of oropharyngeal tumor organoids for disease modeling and high throughput drug screening. Krishna Bommakanti, David Geffen School of Medicine, University of California, Los Angeles, California.

B016 Role of integrin αvβ3 in actions of steroid hormones in breast cancer. Hung-Yun Lin, Taipei Medical University, Taipei, Taiwan.

B020 Predicting DCIS upstaging using eco-evolutionary guided biomarkers of tumor microenvironment. Mehdi Damaghi, Stony Brook University, Stony Brook, New York.

B021 Influenza-induced inflammatory response reactivates and promotes dormant breast cancer cell outgrowth in lungs. Bryan J. Johnson, University of Colorado Anschutz Medical Campus, Aurora, Colorado.

B022 A gradient expression of integrin αvβ6 expression in human cancer cells associates with TGFβ mediated immune evasion. William J. MacDonald, Brown University, Legorreta Cancer Center, Providence, Rhode Island.

B023 Paracrine enhancement of tumor cell proliferation provides indirect stroma-mediated chemoresistance via acceleration of tumor recovery between chemotherapy cycles. Daria Miroshnychenko, Moffitt Cancer Center, Tampa, Florida.


B025 Spatially informed profiling of stage I lung adenocarcinoma reveals an extensive gene expression signature of vascular invasion. Dylan Steiner, Boston University, Boston, Massachusetts.

B026 Dissecting the pancreatic cancer microenvironment using landscape ecology. Merih D. Toruner, Brown University, Providence, Rhode Island.


B029 Centuries of genome instability and evolution in soft-shell clam (Mya arenaria) transmissible cancer. Samuel F. M. Hart, University of Washington, Seattle, Washington.


B038 A preliminary study on predicting pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer. Xi Chen, University of Kansas Medical Center, Kansas City, Kansas.


B041  Identification of m3C modification sites within mRNAs of pancreatic cancer cells by long-read direct RNA sequencing. Kenzui Taniue, Isotope Science Center, The University of Tokyo, Tokyo, Japan.


B043  Quantifying selection intensity and epistatic interactions among gene variants within angiosarcoma. Caralynn E. Hampson, Emmanuel College, Boston, Massachusetts.

B044  Fasciation in saguaro cacti. Is it cancer? Gissel V. Marquez Alcaraz, Arizona State University, Tempe, Arizona.